PRINCETON, N.J., August 26, 2026
Bristol Myers Squibb presented new long-term data for Camzyos® (mavacamten) at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, reinforcing the company’s continued focus on long-term treatment outcomes in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The findings came from the EXPLORER-LTE cohort of the MAVA-LTE study, providing follow-up data of up to five years for patients who previously completed the Phase 3 EXPLORER-HCM study. According to Bristol Myers Squibb, the latest findings add to the extensive clinical evidence supporting Camzyos and demonstrate sustained clinical benefit and a consistent safety profile with continued treatment. The company also presented additional real-world evidence from the COLLIGO-HCM program and other observational analyses at ESC Congress, further expanding the evidence base surrounding Camzyos in routine clinical practice.
Bristol Myers Squibb Highlights Long-Term Camzyos Benefits
Bristol Myers Squibb reported that the EXPLORER-LTE findings provide additional evidence supporting the sustained effects of Camzyos in symptomatic oHCM. The long-term extension enrolled 231 patients from the original EXPLORER-HCM study and evaluated the continued safety and efficacy of treatment. At 252 weeks, Camzyos was associated with sustained reductions in left ventricular outflow tract (LVOT) obstruction, while many patients experienced improvements in functional status measured by NYHA class. The company reported that nearly all evaluated patients achieved a Valsalva LVOT gradient of 30 mm Hg or less, while 69.6% improved by at least one NYHA class and 59.2% were asymptomatic at the assessment. Bristol Myers Squibb also noted that mean left ventricular ejection fraction remained within the normal range despite a reduction from baseline, and no new safety signals were identified beyond those already observed in the original EXPLORER-HCM study.
Company Expands Real-World Evidence for Camzyos
The ESC Congress presentations also strengthened the Bristol Myers Squibb real-world evidence program for Camzyos. Data from COLLIGO-HCM, a global retrospective real-world study, added further support for the effectiveness and safety profile observed in clinical trials. The company reported that patients treated with Camzyos in real-world settings experienced improvements in symptoms and reductions in LVOT obstruction, with findings remaining consistent across patient populations. Additional analysis from a German observational registry supported the effectiveness of Camzyos across geographic populations, including reductions in NYHA functional class. Bristol Myers Squibb also highlighted healthcare resource utilization findings from Sweden, which provided additional insight into the broader burden associated with hypertrophic cardiomyopathy and the importance of appropriate diagnosis and ongoing management. Together, these studies are intended to help clinicians better understand the long-term and real-world impact of Camzyos in symptomatic oHCM.
Advertisement
Bristol Myers Squibb Strengthens Cardiovascular Portfolio
The latest ESC 2026 data represent another step in Bristol Myers Squibb’s cardiovascular development and evidence-generation strategy, with Camzyos positioned as one of the company’s key therapies for symptomatic oHCM. Camzyos is a selective, reversible cardiac myosin inhibitor designed to reduce excessive cardiac contractility, a central mechanism contributing to obstruction in oHCM. Bristol Myers Squibb stated that the medicine has the most extensive worldwide evidence base among cardiac myosin inhibitors, including long-term follow-up and real-world studies. At the same time, the company continues to emphasize the importance of monitoring because Camzyos can reduce left ventricular ejection fraction and carries a risk of heart failure due to systolic dysfunction. Bristol Myers Squibb’s presentation at ESC Congress 2026 therefore combines long-term clinical evidence with real-world experience, supporting the company’s continued efforts to advance treatment options for patients living with symptomatic oHCM.
Source:Bristol Myers Squibb, press relese
